BioMarin (NASDAQ: BMRN) of San Rafael paired with one-year-old Swiss company DiNAQOR AG to develop gene therapies to treat rare genetic heart diseases and Adverum Biotechnologies Inc. (NASDAQ: ADVM) of Redwood City reported that the latest cohort in its early-stage clinical trial of patients with a blinding eye disease had fewer adverse events and patients in an earlier cohort had gone a year since their one and only injection.